Ignite Creation Date:
2024-07-17 @ 12:05 PM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06461598
Status:
COMPLETED
Last Update Posted:
2024-06-17
First Post:
2024-06-11
Brief Title:
Signature for Precise Chemosensitivity Prediction in PDAC
Sponsor:
Ruijin Hospital
Organization:
Ruijin Hospital
Study Overview
Official Title:
Development and Validation of the ChemoResist Signature Precisely Predictive of Chemotherapy Sensitivity in Resected Pancreatic Ductal Adenocarcinoma
Status:
COMPLETED
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Pancreatic ductal adenocarcinoma PDAC is largely heterogeneous We sought to develop and validate a signature to precisely predict chemotherapy sensitivity in PDAC Genetic events of the four most commonly mutated genes in PDAC and expressions of 12 PI3KAKTmTOR pathway markers were examined in consecutive patients with PDAC A 9-feature signature for prediction of chemotherapy benefits was constructed using the LASSO Cox regression model and validated in two independent cohorts
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None